SCHEMBL2449657

SCHEMBL2449657

Cc1cc(C)c(-c2cccc(O[PH](=O)Oc3cccc(-c4c(C)cc(C)cc4C)c3-c3c(C)cc(C)cc3C)c2-c2c(C)cc(C)cc2C)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 4/20 0.33
MAPT P10636 3/20 0.33
ELANE P08246 3/20 0.33
KDM4E B2RXH2 2/20 0.33
TSHR P16473 2/20 0.33
MAPK1 P28482 2/20 0.33
USP2 O75604 1/20 0.33
CYP3A4 P08684 1/20 0.33
BRCA1 P38398 1/20 0.33
RECQL P46063 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
TOP1 P11387 1/20 0.33
APAF1 O14727 1/20 0.33
MITF O75030 1/20 0.33
HTT P42858 1/20 0.33
CRHR1 P34998 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2449658 0.88 PDK2 (0.33) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL1884446 0.77 CRHR1 (0.36) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL8468310 0.77 CRHR1 (0.34) LMNASMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL8468313 0.75 PDK2 (0.35) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL1884447 0.74 PDK2 (0.37) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL28811047 0.74 PDK2 (0.37) MEN1KMT2AALDH1A1MAPTELANE
SCHEMBL3750200 0.70 CRHR1 (0.37) MEN1KMT2AALDH1A1MAPTELANE
SCHEMBL28166102 0.70 TOP1 (0.40) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL16050969 0.69 CRHR1 (0.39) MEN1KMT2AALDH1A1MAPTELANE
SCHEMBL14451012 0.68 APP (0.52) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461236-B2 Phosphoric compound, method for preparing the same, and flame retardant thermoplastic resin composition including the same CHEIL INDUSTRIES INC. (KR) 2013-06-11 US claimed
US-20110263768-A1 Phosphoric Compound, Method for Preparing the Same, and Flame Retardant Thermoplastic Resin Composition Including the Same CHEIL INDUSTRIES INC. (KR) 2011-10-27 US claimed
US-8461236-B2 Phosphoric compound, method for preparing the same, and flame retardant thermoplastic resin composition including the same CHEIL INDUSTRIES INC. (KR) 2013-06-11 US disclosed
US-20110263768-A1 Phosphoric Compound, Method for Preparing the Same, and Flame Retardant Thermoplastic Resin Composition Including the Same CHEIL INDUSTRIES INC. (KR) 2011-10-27 US disclosed
EP-2364986-A1 NOVEL PHOSPHATE COMPOUNDS, PREPARATION METHOD THEREOF, AND FLAME-RETARDANT THERMOPLASTIC RESIN COMPOSITIONS USING SAME Cheil Industries Inc. (KR) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263768-A1 Phosphoric Compound, Method for Preparing the Same, and Flame Retardant Thermoplastic Resin Composition Including the Same PFAS, PPA1, ATIC MEN1 2678/4885KMT2A 932/4885LMNA 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.